All Oncology News

Lan G. Coffman, MD, PhD, discusses pivotal trials evaluating frontline maintenance therapy in advanced ovarian cancer and unanswered questions that still need to be addressed with future research.

David D. Thiel, MD, provides perspective on the CARMENA findings in metastatic renal cell carcinoma.

Pashtoon M. Kasi, MBBS, MD, MS, discusses the use of ctDNA testing throughout treatment for patients with colorectal cancer and ongoing research on liquid biopsies.

A new drug application will be submitted to the FDA under accelerated approval status for lurbinectedin monotherapy for the second-line treatment of patients with small cell lung cancer, according to PharmaMar, the developer of the marine-derived agent.

Terry L. Evans, MD, discusses the use of PARP inhibitors in ovarian cancer and how they are poised to optimally fit in the treatment paradigm.

Kerry A. Rogers, MD, highlights the findings of a study examining acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia and the next steps for the data.

The FDA has approved fedratinib (Inrebic) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis.

Treatment with the cryopreserved autologous tumor-infiltrating lymphocyte therapy lifileucel (LN-144) elicited a 38% objective response rate in heavily pretreated patients with metastatic melanoma.

Hans-Christian Kolberg, MD, discusses the design of the LILAC study, the cardiac safety profiles of ABP 980 and reference trastuzumab, and patient and provider comfort with ABP 980 in practice.

Combining the PARP inhibitor olaparib (Lynparza) with temozolomide (Temodar) led to an overall response rate of 41.7% in patients with relapsed small cell lung cancer.

The FDA has granted an accelerated approval to entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor a NTRK fusion, and has also approved the agent for the treatment of adults with ROS1-positive, metastatic non–small cell lung cancer.

Badi El-Osta, MD, discusses the targeted agents that are showing the most promise for patients with non–small cell lung cancer who have rare alterations and variants.

Simon Rule, MD, PhD, discusses the current treatment options in mantle cell lymphoma and explained how anticipated research results could be integrated into the field.

Leticia Varella, MD, discusses the progression of available treatments in hormone receptor-positive, HER2-negative metastatic breast cancer.

Hope S. Rugo, MD, discusses the findings from the phase III SOPHIA trial and the potential impact of margetuximab on HER2-positive metastatic breast cancer.

Data from several clinical trials support treatment with lenalidomide (Revlimid) plus low-dose dexamethasone in select patients with high-risk smoldering multiple myeloma to prevent disease progression and other promising combinations under investigation are showing curative potential.

The emergence of monoclonal antibodies, immunomodulatory agents, immunotoxins, bispecific T-cell engagers, and CAR T-cell therapies will redefine multiple myeloma treatment. However, these new approaches, by themselves, are not enough to achieve cure; they must be used in combination.

The FDA has granted a breakthrough therapy designation to acalabrutinib (Calquence) for the treatment of patients with chronic lymphocytic leukemia.

Combining olaparib with standard bevacizumab significantly improved progression-free survival compared with bevacizumab alone as frontline maintenance therapy in women with advanced ovarian cancer, regardless of BRCA status, according to topline results from the phase III PAOLA-1 trial.

Saul Priceman, PhD, City of Hope assistant professor in the Department of Hematology & Hematopoietic Cell Transplantation, and his research team have received a $9.28 million award from the California Institute for Regenerative Medicine to support a chimeric antigen receptor T cell phase 1 clinical trial for the treatment of women with HER2-positive breast cancer that has spread to the brain.

Peter Voorhees, MD, discusses the recent data with triplet regimens in late relapsed multiple myeloma and other novel agents shaking up the paradigm.

The European Commission has expanded the approval of ibrutinib to include use in combination with obinutuzumab for adult patients with previously untreated chronic lymphocytic leukemia, and also in combination with rituximab for the treatment of adult patients with Waldenström macroglobulinemia.

Rathi N. Pillai, MD, discusses the basis for frontline combinations of chemotherapy and immunotherapy in advanced nonsquamous non–small cell lung cancer and questions surrounding the optimal sequence of these agents.

The goal of induction regimens for patients with newly diagnosed multiple myeloma is to reduce the burden of disease and prolong durability of response and overall survival, while minimizing toxicity.

Conor E. Steuer, MD, discusses emerging agents in the treatment of patients with ALK- or ROS1-positive non–small cell lung cancer and the sequencing challenges that have resulted in the space.

Ripretinib (DCC-2618) improved progression-free survival compared with placebo in patients with fourth-line and fourth-line plus advanced gastrointestinal stromal tumors, according to topline findings of the phase III INVICTUS study (NCT03353753).

Vicinium led to 6- and 12-month complete response rates in patients with high-risk non-muscle invasive bladder cancer who did not respond to Bacillus Calmette-Guérin therapy, according to updated results of the phase III VISTA trial.

Sarah E. Taylor, MD, discusses the role of somatic and germline testing for patients with ovarian cancer and their family members to create more personalized treatment and prevent disease.

Winston Tan, MD, discusses the influx of treatment options in nonmetastatic castration-resistant prostate cancer and the modalities that are being used in an effort to ensure their optimal use.

Jennifer W. Carlisle, MD, highlights the research surrounding immunotherapy in frontline lung cancer treatment.